Breaking News

This Pharmaceutical Company Has a Brilliant Concept

Contributed Opinion
  ()
Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. Catalysts abound with this genius repurposing company.

US Cannabis Firm in 'State of Flux'

Research Report
  ()
With several market factors working against Stem Holdings, its future is uncertain, noted a Noble Capital Markets report.
Tags:  Cannabis

Derm Biopharma Named Top Growth Pick For 2022

Research Report
  ()
Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024, noted a ROTH Capital Partners report.

Biotech Could Launch Trial of Polyp Screening Test in March

Research Report
  ()
The start of the C-Scan study would be a major milestone for Check-Cap, noted an H.C. Wainwright & Co. report.

Ph1 Trial Results of Dementia Drug Positive

Research Report
  ()
Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report.

Biotech Co. Partners With Life Sciences Firms

Research Report
  ()
2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report.

2022 to Be Catalyst Rich for Biopharma

Research Report
  ()
The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report.

Enrollment Done for COVID-19 Drug Trial

Research Report
  ()
Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report.

AI Driven Drug Firm Partners With Merck

  ()
Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creation™ platform and Bionic Protein™ technologies.

Co.'s samRNA Vaccines Protect Better Against COVID Variants

Research Report
  ()
Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio.

Medical Co. Strikes $3B Deal to Buy Digital Care Firm

  ()
Shares of Vocera Communications Inc. traded nearly 27% higher after the company reported it entered into a definitive agreement to be acquired by Stryker Corp. for $79.25 per share in cash.

Co. Partners to Test New Cancer Vaccines

Research Report
  ()
Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea.

Chen Lin's Top 6 Investment Ideas

  ()
In a recent interview with Streetwise Reports, family assets manager and contributing writer, Chen Lin, shared the six (mostly mid-cap) companies that are his top investment picks for 2022.

Expert Investing Ideas

"We could soon see some good gains in AGN."

–Clive Maund, CliveMaund.com


"AGN's risk/reward profile is attractive."

–André Uddin, Research Capital Corporation


"AGN is switching focus to the IPF/chronic cough indication."

–André Uddin, Research Capital Corporation


"AGN requested a meeting with the FDA to discuss advancing ifenprodil."

–André Uddin, Research Capital Corporation


"Final results from AGN's Phase 2b COVID-19 trial are expected soon."

–André Uddin, Research Capital Corporation


"AGN is to continue a number of preclinical studies of DMT for stroke."

–André Uddin, Research Capital Corporation


"AGN [shares] are now in a vigorous uptrend."

–Clive Maund, CliveMaund.com


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

New Muscular Dystrophy Drug Shows Promise

  ()
Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial.

Co. Plans to Make 100M Rapid COVID Tests Monthly

Research Report
  ()
Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22.

Lead Cancer Drug Gets Fast Tracked

  ()
Shares of Genprex Inc. traded 165% higher after the company reported the U.S. FDA has awarded Fast Track Designation for its REQORSA™ Immunogene Therapy for use in combination with Merck & Co.'s Keytruda® for non-small cell lung cancer treatment.

Analyst: Drug a 'Hidden Gem for 2022'

Research Report
  ()
Oppenheimer ranks Astria Therapeutics Outperform after learning about its drug for hereditary angioedema, saying "We stay bullish."

Co.'s COVID-19 Test Detects Omicron Variant

Research Report
  ()
H.C. Wainwright & Co. gives Sorrento Therapeutics a Buy rating after initial testing shows its COVISTIX detects COVID-19's Omicron variant.

Co. Looks To US For Help Fighting Strokes

  ()
Canadian company Algernon Pharmaceuticals Inc. has applied to uplist to the Nasdaq in hopes of attracting U.S. investors to its mission to repurpose drugs.